Hosted on MSN4h
Lundbeck gains FDA fast track designation for MSA therapy amlenetug
The designation will provide Lundbeck with the possibility of rolling reviews and detailed guidance to streamline the drug ...
The link between renal failure and Parkinson's disease: Researchers illuminate the underlying mechanisms
Lewy body diseases (LBDs) are a class of debilitating neurodegenerative disorders linked to the abnormal aggregation of the ...
PharmaTimes17h
Amlenetug receives FDA Fast Track Designation
Amlenetug received Orphan Drug Designation (ODD) from the US FDA in April 2024, the EMA in May 2021 and SAKIGAKE designation ...
EurekAlert!2y
α-synuclein aggregates as seen on a PET scan in patients with MSA and a healthy control (IMAGE)
Researchers visualize α-synuclein pathology in living patients with a neurodegenerative disorder The National Institutes for Quantum Science and Technology Journal Movement Disorders DOI 10.1002 ...
Knowridge7d
New research links kidney failure to Parkinson’s disease
Now, a new study from Renmin Hospital of Wuhan University provides strong evidence that kidney failure may also contribute to the development of Parkinson’s disease by triggering the spread of ...
Phys.org28d
Nanoparticles restore neurons in Parkinson's with wireless brain stimulation
Its pathological hallmark is the abnormal aggregation of α-synuclein (α-syn) into insoluble fibrils and Lewy bodies, leading to the degeneration and death of dopaminergic neurons in the ...
Lundbeck's potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA
H. Lundbeck A/S (Lundbeck) today announced that amlenetug has received Fast Track designation from the United States (US) Food and Drug Administration (FDA).